The brain's transporters: a field guide

How the proteins that clear, recycle and load neurotransmitters work, what each does in brain and body, and which medicines act on them.

Vicente27 min read

A neurotransmitter signal is shaped as much by how it ends as by how it starts. Receptors read the message. Transporters decide how long it lasts, how far it spreads, and whether there is enough transmitter left for the next one.

Every transporter in this post does one of four jobs:

  • Clear. Pull transmitter out of the synapse so the signal stops.
  • Recycle. Return it to the cell that released it, or to a neighbouring glial cell, for reuse.
  • Load. Pack it into vesicles so it can be released again.
  • Supply. Carry fuel and raw materials across the blood-brain barrier.

This is also where much of psychiatry's pharmacology acts. Most antidepressants, the main ADHD medications, one class of anti-seizure drug and the treatments for tardive dyskinesia all work by changing what a transporter does.

This post is one of three. The companion posts cover the neurotransmitters these transporters carry and the receptors that read them.

#How this list was prioritized

The human genome encodes more than 400 solute carrier (SLC) transporters. This post covers about 25, ranked by impact: how much of brain function depends on the transmitter, and how much clinical leverage the transporter gives us.

  1. Glutamate and GABA come first. They carry the large majority of fast signalling in the brain, as its main accelerator and brake.
  2. Serotonin, dopamine and noradrenaline come next. Few neurons use them, but they tune mood, motivation, attention and arousal across the whole brain.
  3. Vesicular loaders, glycine and acetylcholine follow, then a supporting cast and the blood-brain barrier supply chain.

Each transporter section is self-contained and follows the same order: what it is, how it works, what it does in the brain and body, its role in psychiatric and neurological conditions, and the drugs that act on it.

#The shared mechanics

Almost every transporter here works the same way: it borrows energy from an ion gradient to move its cargo uphill. Learn this once and each later section becomes a variation on it.

#Alternating access

A channel is an open pore. A transporter is a revolving door: it is never open to both sides of the membrane at once.

  1. It opens outward and binds its cargo plus one or more ions.
  2. It closes over them.
  3. It opens inward and releases them.
  4. It resets to face outward again.
[diagram]
A transporter is never open to both sides at once
01Open outward
Faces the synapse. Binds transmitter and sodium ions.
02Closed over cargo
Both gates shut. The cargo is sealed inside the protein.
03Open inward
Faces the cell interior. Releases transmitter and sodium ions.
04Reset
Returns empty, or carrying potassium out, to face outward again.
The sodium gradient drives the cycle in one direction.
1. Open outward leads to 2. Closed over cargo (outer gate closes)
2. Closed over cargo leads to 3. Open inward (inner gate opens)
3. Open inward leads to 4. Reset (cargo leaves)
4. Reset leads to 1. Open outward (flips back)

This makes transporters far slower than channels, moving roughly one to a few hundred molecules per second each. It also lets them concentrate cargo thousands of times over, which no channel can do.

#Where the energy comes from

Transporters do not burn ATP directly. They spend gradients that pumps have already built.

  • At the cell surface, the currency is sodium. The Na+/K+ pump keeps sodium high outside the cell. Plasma-membrane transporters let sodium flow in and drag transmitter along with it.
  • At the vesicle, the currency is protons. A proton pump acidifies the vesicle interior. Vesicular transporters let protons flow out and swap transmitter in.

This is why energy failure, as in a stroke, is so dangerous. When the sodium gradient collapses, surface transporters stop clearing transmitter and can run backwards.

#Two locations, two jobs

Plasma-membrane transportersVesicular transporters
Sit onThe cell surface of neurons and gliaSynaptic vesicles inside the terminal
JobClear and recycleLoad for release
Driven bySodium, often with chloride or potassiumProtons
ExamplesSERT, DAT, NET, EAATs, GATsVMAT2, VGLUTs, VGAT, VAChT

#The families

Transporters are grouped into solute carrier (SLC) families by sequence. Five families cover most of this post.

FamilyMembers covered hereCarries
SLC1EAAT1 to EAAT5Glutamate
SLC6SERT, DAT, NET, GATs, GlyTsMonoamines, GABA, glycine
SLC17VGLUT1 to VGLUT3Glutamate, into vesicles
SLC18VMAT1, VMAT2, VAChTMonoamines and acetylcholine, into vesicles
SLC32VGATGABA and glycine, into vesicles

A gene name such as SLC6A4 reads as family 6, subfamily A, member 4. That gene encodes SERT.

#Map at a glance

Every transporter in this post, in the order it appears. Rows are sorted by impact, highest first.

[diagram]
Loaders sit on vesicles, recyclers on terminals, cleaners on astrocytes
Presynaptic terminal
Vesicle: load
VMAT2monoamines
VGLUT1-3glutamate
VGATGABA, glycine
VAChTacetylcholine
Surface: clear and recycle
SERTserotonin
DATdopamine
NETnoradrenaline
GAT1GABA
GlyT2glycine
CHT1choline
Synaptic cleft
Transmitter is released here and cleared by the transporters around it.
Astrocyte: clear
EAAT1, EAAT2glutamate
GAT3GABA
GlyT1glycine
System xc-cystine/glutamate
SNAT3, SNAT5glutamine out
Postsynaptic neuron
EAAT3glutamate, cysteine
PMAT, OCT3monoamines (also on glia)
Blood-brain barrier: supply
GLUT1glucose in
LAT1amino acids in
MCT1lactate, ketones in
P-glycoproteindrugs out
Vesicle: load leads to Synaptic cleft (release)
Synaptic cleft leads to Surface: clear and recycle (reuptake)
Synaptic cleft leads to Astrocyte: clear (glial uptake)
Synaptic cleft leads to Postsynaptic neuron (signal)
Blood-brain barrier: supply leads to Astrocyte: clear (fuel and precursors)

Transmitter leaves the vesicle, crosses the cleft, and is then taken back by the terminal or cleared by the astrocyte beside it.

TransporterGeneCarriesMainly found onJobMedicines that act on it
EAAT2 (GLT-1)SLC1A2GlutamateAstrocytesClearNone approved
EAAT1 (GLAST)SLC1A3GlutamateAstrocytes, cerebellar gliaClearNone approved
EAAT3SLC1A1Glutamate, cysteineNeuronsClear, supplyNone approved
GAT1SLC6A1GABAGABA neuron terminalsClear, recycleTiagabine
GAT3SLC6A11GABAAstrocytesClearNone approved
SERTSLC6A4SerotoninSerotonin neurons, platelets, gutClear, recycleSSRIs, SNRIs, tricyclics
DATSLC6A3DopamineDopamine neuronsClear, recycleMethylphenidate, amphetamine salts, bupropion
NETSLC6A2Noradrenaline, dopamineNoradrenaline neuronsClear, recycleAtomoxetine, SNRIs, tricyclics, bupropion
VMAT2SLC18A2All monoaminesVesicles of monoamine neuronsLoadTetrabenazine, valbenazine, deutetrabenazine
VGLUT1 to 3SLC17A7, A6, A8GlutamateVesicles of glutamate neuronsLoadNone approved
VGATSLC32A1GABA, glycineVesicles of inhibitory neuronsLoadNone approved
GlyT1SLC6A9GlycineAstrocytes, some glutamate terminalsClearNone approved; phase 3 trials negative
GlyT2SLC6A5GlycineGlycine neuron terminalsRecycleNone approved
CHT1SLC5A7CholineCholinergic terminalsRecycleNone approved
VAChTSLC18A3AcetylcholineVesicles of cholinergic neuronsLoadNone approved
PMAT, OCT3SLC29A4, SLC22A3MonoaminesNeurons and glia, widelyClear, low affinityNone approved
ENT1SLC29A1AdenosineNeurons and glia, widelyClearDipyridamole (used outside psychiatry)
System xc-SLC7A11Cystine in, glutamate outAstrocytesExchangeN-acetylcysteine acts through it
GLUT1SLC2A1GlucoseBlood-brain barrierSupplyKetogenic diet bypasses it
LAT1SLC7A5Large amino acidsBlood-brain barrierSupplyCarries levodopa, gabapentin

#EAATs: the glutamate transporters

The excitatory amino acid transporters keep the brain's main excitatory transmitter from poisoning it. Glutamate has no enzyme that breaks it down in the synapse, so uptake is the only way the signal ends.

Transmitter: glutamate. Family: SLC1. Job: clear.

#The five subtypes

SubtypeOther nameMainly found onNote
EAAT2GLT-1Astrocytes, forebrainDoes about 95% of forebrain glutamate uptake
EAAT1GLASTAstrocytes, cerebellar Bergmann gliaDominant in cerebellum and during development
EAAT3EAAC1Neurons, on cell bodies and dendritesAlso imports cysteine for antioxidant synthesis
EAAT4Cerebellar Purkinje cellsBehaves partly as a chloride channel
EAAT5RetinaBehaves mostly as a chloride channel

#Mechanism

Each cycle carries one glutamate into the cell with three sodium ions and one proton, then returns one potassium ion outward. Coupling to three sodium ions lets the transporter hold resting glutamate outside cells about a million times lower than inside.

The work is done mostly by astrocytes, not neurons. Astrocytes convert the glutamate to glutamine, which is inert at receptors, and hand it back to neurons to be remade into glutamate. This loop is the glutamate-glutamine cycle.

[diagram]
Glutamate is recycled through the astrocyte, not taken straight back
Glutamate neuron
Astrocyte
01Glutamate released
loaded into vesicles by VGLUT
02Taken up by EAAT1, EAAT2
this step ends the signal
03Converted to glutamine
by glutamine synthetase
04Rebuilt into glutamate
by glutaminase, or on to GABA
SNAT3 and SNAT5 release glutamine from the astrocyte; SNAT1 and SNAT2 take it up into the neuron.
1. Glutamate released leads to 2. Taken up by EAAT1, EAAT2 (across the cleft)
2. Taken up by EAAT1, EAAT2 leads to 3. Converted to glutamine
3. Converted to glutamine leads to 4. Rebuilt into glutamate (glutamine shuttle)
4. Rebuilt into glutamate leads to 1. Glutamate released

#What it does

  • Ends the signal and keeps one synapse from spilling into its neighbours, which preserves precision.
  • Prevents excitotoxicity. Sustained glutamate over-activates receptors and floods neurons with calcium, which kills them.
  • Feeds GABA synthesis. Recycled glutamate is also the precursor for GABA.
  • In the body, EAAT3 reabsorbs glutamate and aspartate in the kidney and gut.

#When it goes wrong

  • Stroke and energy failure. When the sodium gradient collapses, EAATs stall and then reverse, releasing glutamate. This is a main driver of damage after ischaemia.
  • ALS. Loss of EAAT2 is found in the motor cortex and spinal cord of many patients. Riluzole, the first approved ALS drug, reduces glutamate signalling.
  • Epilepsy. Mice without EAAT2 die of seizures. Reduced astrocyte uptake is reported in human epileptic tissue.
  • Episodic ataxia type 6. Caused by mutations in the EAAT1 gene.
  • Psychiatry. Altered glial glutamate transporter expression is reported in depression, schizophrenia and addiction. Variants in the EAAT3 gene have been linked to OCD. These findings are associations, not established causes.

#Drugs

No approved medicine targets an EAAT directly. The antibiotic ceftriaxone raises EAAT2 expression in animals, but it failed in the final stage of a large ALS trial in 2014. Raising EAAT2 activity remains an active research goal.

#GATs: the GABA transporters

The GABA transporters set the strength and duration of inhibition, the brain's main brake. They control both the brief inhibition at synapses and the steady background inhibition around them.

Transmitter: GABA. Family: SLC6. Job: clear and recycle.

#The four subtypes

SubtypeGeneMainly found onNote
GAT1SLC6A1Terminals of GABA neurons, some astrocytesThe main brain GABA transporter
GAT3SLC6A11AstrocytesControls GABA levels outside the synapse
GAT2SLC6A13Meninges, liver, kidneyMinor role in brain tissue
BGT1SLC6A12Kidney, liver, low levels in brainAlso carries betaine, used for cell volume control

#Mechanism

Each cycle carries one GABA into the cell with two sodium ions and one chloride ion. GAT1 returns GABA to the terminal that released it, where it is reloaded into vesicles. GABA taken up by astrocytes through GAT3 is broken down by GABA transaminase.

#What it does

  • Shapes phasic inhibition. GAT1 limits how long each inhibitory pulse lasts at the synapse.
  • Sets tonic inhibition. GAT1 and GAT3 fix the low background GABA level that acts on receptors outside synapses. This sets how excitable a whole circuit is.
  • Keeps rhythms in time. Fast inhibitory timing underlies the gamma oscillations linked to attention and working memory.

#When it goes wrong

  • SLC6A1 disorders. Loss of one working copy of the GAT1 gene causes epilepsy with myoclonic-atonic seizures, developmental delay and often autism.
  • Absence seizures. In animal models, reduced GAT1 function in the thalamus raises tonic inhibition and produces absence seizures. Too much inhibition in the wrong place can cause seizures too.
  • Anxiety and sleep. Both depend on GABA tone, which is why GAT1 has been studied as a target for each.

#Drugs

  • Tiagabine selectively blocks GAT1 and raises synaptic GABA. It is approved as add-on treatment for focal seizures.
  • A caution worth knowing. Tiagabine has triggered seizures in people without epilepsy when used off-label. This fits the absence-seizure finding above.
  • Vigabatrin is not a transporter drug, but it is the useful contrast. It raises GABA by blocking its breakdown instead of its uptake.

#SERT: the serotonin transporter

SERT is the most commonly targeted protein in psychiatric prescribing. One transporter, made from one gene, clears serotonin in the brain, the gut and the blood.

Transmitter: serotonin (5-HT). Gene: SLC6A4. Family: SLC6. Job: clear and recycle.

#Where it sits

  • Brain. On serotonin neurons, whose cell bodies lie in the raphe nuclei of the brainstem and project almost everywhere. SERT sits around the synapse, not inside it, so serotonin spreads before it is cleared.
  • Gut. About 95% of the body's serotonin is made in the gut wall. SERT on the gut lining clears it after it has triggered motility and secretion.
  • Platelets. Platelets cannot make serotonin. They collect it from blood through SERT and release it during clotting.

#Mechanism

Each cycle carries one serotonin into the cell with one sodium ion and one chloride ion, then returns one potassium ion outward. Recovered serotonin is reloaded into vesicles by VMAT2 or broken down by monoamine oxidase.

#What it does

SERT sets the level and reach of serotonin signalling. In the brain, serotonin tunes mood, anxiety, impulse control, sleep, appetite and pain. In the body, it governs gut motility, platelet clotting and blood vessel tone.

#Drugs

ClassExamplesBlocks
SSRIsSertraline, escitalopram, fluoxetineSERT
SNRIsVenlafaxine, duloxetineSERT and NET
TricyclicsClomipramine, amitriptylineSERT and NET, plus several receptors

These are used for depression, anxiety disorders, OCD, PTSD and bulimia. Three facts explain most of what patients experience:

  1. Blockade is fast, benefit is slow. Standard doses occupy about 80% of SERT within hours. Improvement takes two to six weeks, so the benefit comes from slower adaptation downstream, not from raised serotonin itself.
  2. Side effects follow the body map. Nausea and loose stools come from gut SERT. A small rise in bleeding risk comes from platelets running low on serotonin.
  3. Combining serotonin-raising drugs is dangerous. Pairing a SERT blocker with a monoamine oxidase inhibitor can cause serotonin syndrome.

#When it goes wrong

  • Depression and anxiety. SERT blockers work, but low serotonin as the cause of depression is not supported by current evidence. The treatment working does not prove the deficiency.
  • The 5-HTTLPR story. A common variant in the SERT gene's promoter was once thought to make people vulnerable to depression after stress. Large later studies did not confirm it.
  • OCD. It responds to SERT blockers specifically, often at higher doses and after longer delays than depression.
  • Irritable bowel syndrome. Altered gut SERT expression has been reported, consistent with serotonin's role in motility.

#DAT: the dopamine transporter

DAT decides how long a dopamine signal lasts in the striatum, the brain's hub for movement, motivation and learning from reward. In mice bred without it, released dopamine lingers at least 100 times longer, and the animals are markedly hyperactive.

Transmitter: dopamine. Gene: SLC6A3. Family: SLC6. Job: clear and recycle.

#Where it sits

DAT is found only on dopamine neurons. Its density differs sharply by region, and this explains a lot.

RegionDAT densityDopamine is cleared mainly byFunction
Dorsal striatumVery highDATMovement, habits
Ventral striatum (nucleus accumbens)HighDATMotivation, reward learning
Prefrontal cortexVery lowNET and the enzyme COMTWorking memory, attention

#Mechanism

Each cycle carries one dopamine into the cell with two sodium ions and one chloride ion. Like SERT, DAT sits beside the synapse, so dopamine diffuses and acts on nearby cells before it is recovered.

#What it does

  • Times the reward signal. Brief bursts of dopamine mark outcomes that were better than expected. DAT keeps these bursts brief, so they stay informative.
  • Sets movement tone. Steady striatal dopamine permits smooth, willed movement.
  • Recycles. Most released dopamine is reused, not newly made, so DAT also maintains the supply.

#Drugs

  • Methylphenidate blocks DAT and NET. It is a first-line ADHD treatment.
  • Amphetamine-based ADHD medicines act on DAT, NET and VMAT2 to raise dopamine and noradrenaline.
  • Bupropion weakly blocks DAT and NET. It is used for depression and smoking cessation.
  • Modafinil weakly blocks DAT and promotes wakefulness.

How quickly a drug occupies DAT matters as much as how fully. Slow, steady occupancy gives therapeutic effect with lower misuse risk, which is why long-acting formulations are preferred.

#When it goes wrong

  • ADHD. Medicines acting on DAT are among the most effective in psychiatry. Whether DAT itself is abnormal in ADHD remains unsettled, as imaging studies conflict.
  • Parkinson's disease. Dopamine terminals die and take their DAT with them. The DaTscan measures striatal DAT to tell Parkinsonian syndromes from essential tremor.
  • DAT deficiency syndrome. Loss of both gene copies causes a rare infant-onset movement disorder with parkinsonism and dystonia.
  • Addiction. Substances with misuse potential share one effect: a fast, large rise in striatal dopamine. DAT is one of the main routes to it.

#NET: the noradrenaline transporter

NET clears noradrenaline in the brain and at sympathetic nerve endings throughout the body. It also clears most of the dopamine in the prefrontal cortex, which makes it a quiet second dopamine transporter.

Transmitters: noradrenaline, and dopamine in the prefrontal cortex. Gene: SLC6A2. Family: SLC6. Job: clear and recycle.

#Where it sits

  • Brain. On noradrenaline neurons. Most arise from the locus coeruleus, a small brainstem nucleus that projects to nearly the whole brain.
  • Body. On sympathetic nerve endings in the heart, blood vessels and other organs. There it recovers most of the noradrenaline those nerves release.

#Mechanism

Each cycle carries one noradrenaline into the cell with one sodium ion and one chloride ion. NET binds dopamine at least as well as noradrenaline. Because the prefrontal cortex has little DAT, NET does the dopamine clearing there.

#What it does

  • Arousal and attention. Noradrenaline raises alertness and sharpens the brain's response to what matters. NET keeps that signal in its useful middle range.
  • Prefrontal function. Working memory depends on moderate levels of both noradrenaline and dopamine. Too little or too much impairs it.
  • Stress response. The locus coeruleus fires hard under threat, driving vigilance.
  • Pain control. Noradrenaline pathways descending to the spinal cord dampen incoming pain signals.
  • Cardiovascular tone. NET limits how strongly sympathetic nerves drive heart rate and blood pressure.

#Drugs

DrugBlocksUsed for
Atomoxetine, viloxazineNETADHD, as non-stimulant options
Venlafaxine, duloxetineSERT and NETDepression, anxiety, nerve pain
Nortriptyline, desipramineMostly NETDepression, nerve pain
Methylphenidate, bupropionDAT and NETADHD; depression

Two consequences follow from the map above. NET blockers help ADHD by raising prefrontal dopamine and noradrenaline without acting much on the striatum. They also tend to raise heart rate and blood pressure, because NET in the body is blocked too.

#When it goes wrong

  • ADHD. NET blockade improves attention and impulse control, which supports a prefrontal catecholamine account of the condition.
  • Depression and chronic pain. Adding NET blockade to SERT blockade helps pain conditions in a way SERT blockade alone usually does not.
  • Orthostatic intolerance. A rare inherited NET mutation causes a racing heart on standing. It was the first transporter mutation tied to a human autonomic disorder.
  • Hyperarousal states. Excess noradrenaline signalling is implicated in the vigilance and sleep disturbance of PTSD.

#VMAT2: the vesicular monoamine transporter

VMAT2 is the single loader for every monoamine in the brain. Dopamine, noradrenaline, serotonin and histamine neurons all depend on it to fill their vesicles, so one drug acting here changes all four systems at once.

Transmitters: dopamine, noradrenaline, serotonin, histamine. Gene: SLC18A2. Family: SLC18. Job: load.

#Where it sits

On the membrane of synaptic vesicles inside monoamine neurons. Its sibling VMAT1 does the same job outside the brain, in the adrenal gland and gut hormone cells.

#Mechanism

A proton pump first acidifies the vesicle. VMAT2 then lets two protons out for each monoamine it brings in. This concentrates transmitter inside the vesicle about 10,000 times over the surrounding cell fluid.

#What it does

  • Sets the size of each signal. How full a vesicle is determines how much transmitter each release delivers.
  • Protects the neuron. Dopamine left loose in the cell oxidizes into reactive, damaging products. Packing it away is a form of detoxification.

#Drugs

Blocking VMAT2 leaves vesicles underfilled, so each release delivers less. This turns monoamine signalling down without blocking any receptor.

DrugUsed forNote
TetrabenazineChorea in Huntington's diseaseReversible, short-acting
DeutetrabenazineHuntington's chorea, tardive dyskinesiaLonger-acting form of tetrabenazine
ValbenazineTardive dyskinesia, Huntington's choreaOnce daily
ReserpineHistorically, high blood pressure and psychosisIrreversible; now rarely used

The main risks follow directly from the mechanism: low mood, sedation and parkinsonism. These drugs carry warnings about depression and suicidal thoughts in Huntington's disease.

#When it goes wrong

  • Tardive dyskinesia. Long-term dopamine receptor blockade can produce involuntary movements. Reducing dopamine release with a VMAT2 inhibitor was the first approach to win regulatory approval for it.
  • Parkinson's disease. Lower VMAT2 activity leaves more loose dopamine in the cell. This may be one reason dopamine neurons are unusually fragile.
  • A piece of history. Some patients on reserpine became depressed in the 1950s. That observation helped launch the monoamine theory of depression, though later analyses found the link weaker than first reported.
  • Rare genetic disease. Loss of VMAT2 function causes an infant-onset disorder of movement, mood and autonomic control.

#VGLUTs and VGAT: the loaders that define a neuron

A neuron is excitatory or inhibitory because of which vesicular transporter it makes. Glutamate is present in every cell as a basic metabolite. Only cells with a VGLUT can release it as a signal.

Transmitters: glutamate (VGLUTs); GABA and glycine (VGAT). Families: SLC17 and SLC32. Job: load.

#The subtypes

TransporterGeneMainly found inNote
VGLUT1SLC17A7Cortex, hippocampus, cerebellar cortexThe loader for most cortical excitatory synapses
VGLUT2SLC17A6Thalamus, brainstem, hypothalamusThe loader for most subcortical excitatory synapses
VGLUT3SLC17A8Scattered serotonin, acetylcholine and GABA neurons; inner ear hair cellsLets non-glutamate neurons also release glutamate
VGATSLC32A1All GABA and glycine neuronsOne loader for both inhibitory transmitters

#Mechanism

Both types run on the vesicle's proton gradient. That gradient has two parts: a chemical part (acidity) and an electrical part (positive charge inside). VGLUTs draw mainly on the electrical part to pull in negatively charged glutamate. VGAT uses both.

#What they do

  • Assign identity. Researchers label a neuron excitatory or inhibitory by staining for VGLUT or VGAT.
  • Set signal size. The number of transporters per vesicle influences how much transmitter each vesicle holds.
  • Enable co-release. VGLUT3 lets some serotonin and acetylcholine neurons send a fast glutamate signal alongside their slower one. VGAT lets some spinal neurons release GABA and glycine together.

#When they go wrong

  • Deafness. A VGLUT3 mutation causes a form of inherited progressive hearing loss, because inner ear hair cells use it to signal sound.
  • Epilepsy. Variants in the VGAT gene have been linked to inherited epilepsy with febrile seizures.
  • Loss is not survivable. Mice lacking VGLUT1, VGLUT2 or VGAT die before or soon after birth, which shows how basic these loaders are.

#Drugs

No approved medicine targets these transporters. They are too widespread and too essential for a blocker to be selective.

#GlyT1 and GlyT2: the glycine transporters

Glycine has two opposite roles, and each has its own transporter. In the spinal cord and brainstem it is an inhibitory transmitter. In the forebrain it is a required helper for the NMDA glutamate receptor, which drives learning.

Transmitter: glycine. Genes: SLC6A9 (GlyT1), SLC6A5 (GlyT2). Family: SLC6. Job: clear (GlyT1), recycle (GlyT2).

#The two subtypes

GlyT1GlyT2
Mainly found onAstrocytes, and near glutamate synapsesTerminals of glycine neurons
RegionThroughout the brain and spinal cordSpinal cord, brainstem, cerebellum
Ions per glycine2 sodium, 1 chloride3 sodium, 1 chloride
Main roleKeeps glycine low around NMDA receptors and ends inhibitory signalsRefills the terminal so vesicles can be reloaded

#Mechanism

Both work like the other SLC6 transporters. The extra sodium ion gives GlyT2 more concentrating power, which it needs to stock glycine terminals to very high levels.

#What they do

  • Inhibition in the spinal cord and brainstem. Glycine restrains motor neurons and gates sensory input, including pain and startle reflexes.
  • Tuning NMDA receptors. An NMDA receptor opens only when glutamate and a co-agonist, glycine or D-serine, are both bound. By holding glycine low, GlyT1 sets how readily these receptors respond.

#When it goes wrong

  • Startle disease (hyperekplexia). GlyT2 mutations leave glycine terminals underfilled. Infants show stiffness and an exaggerated startle to sound or touch.
  • GlyT1 encephalopathy. Loss of GlyT1 causes a severe infant disorder with low muscle tone and breathing difficulty.
  • Schizophrenia. Reduced NMDA receptor function is a leading model for its cognitive and negative symptoms. Blocking GlyT1 should raise glycine and boost those receptors.

#Drugs

The schizophrenia idea has been tested twice at scale and has not held up so far. Bitopertin failed phase 3 trials for negative symptoms. Iclepertin failed phase 3 trials for cognitive symptoms.

Bitopertin is now being developed for a blood disorder, erythropoietic protoporphyria, because red blood cell precursors also need GlyT1 to import glycine for haem synthesis. In February 2026 the FDA declined to approve it for that use until phase 3 results are in. No GlyT2 drug is approved, though GlyT2 blockers are studied for chronic pain.

#CHT1 and VAChT: the acetylcholine supply line

Acetylcholine is the exception to the reuptake rule. Its signal is ended by an enzyme, not a transporter, and what the neuron takes back is a fragment: choline.

Transmitter: acetylcholine. Genes: SLC5A7 (CHT1), SLC18A3 (VAChT). Jobs: recycle (CHT1), load (VAChT).

#The cycle

  1. Acetylcholine is released and acts on its receptors.
  2. The enzyme acetylcholinesterase splits it into choline and acetate within milliseconds.
  3. CHT1 carries the choline back into the terminal, driven by sodium.
  4. The enzyme ChAT rebuilds acetylcholine from choline.
  5. VAChT loads it into vesicles, driven by protons.

Step 3 is the bottleneck. Choline uptake by CHT1 sets the maximum rate at which a neuron can keep making acetylcholine. Under heavy firing, terminals move more CHT1 to the surface to keep up.

#What it does

  • In the brain. Acetylcholine from the basal forebrain supports attention and the encoding of new memories. Brainstem acetylcholine helps drive REM sleep.
  • In the body. It is the transmitter at every nerve-to-muscle junction and throughout the parasympathetic system.

#When it goes wrong

  • Congenital myasthenic syndromes. Mutations in either CHT1 or VAChT cause inherited muscle weakness that worsens with effort, sometimes with dangerous pauses in breathing in infancy.
  • Alzheimer's disease. Basal forebrain cholinergic neurons degenerate early. Imaging agents that bind VAChT are used in research to measure that loss.

#Drugs

No approved medicine targets CHT1 or VAChT. Cholinergic drugs act elsewhere in the cycle. Donepezil and related Alzheimer's drugs block the enzyme in step 2, so each released acetylcholine molecule lasts longer.

#The supporting cast

Four smaller systems fill gaps the main transporters leave. Each gets a short entry, because each explains something the headline transporters cannot.

#Uptake-2: PMAT and OCT3

Carries: serotonin, dopamine, noradrenaline, histamine. Genes: SLC29A4 (PMAT), SLC22A3 (OCT3).

SERT, DAT and NET bind tightly but saturate quickly. PMAT and OCT3 bind loosely but have large capacity, and they do not need sodium. They sit widely on neurons and glia and mop up monoamines that escape the main transporters.

  • Why it matters. In animals, uptake-2 keeps clearing serotonin when SERT is blocked. This may be one reason SSRIs help some people only partly.
  • Stress link. OCT3 is inhibited by the stress hormone corticosterone, a possible route by which stress alters monoamine signalling.

#ENT1 and adenosine

Carries: adenosine. Gene: SLC29A1.

Adenosine builds up as cells spend energy and acts as the brain's fatigue signal. Its accumulation during waking creates sleep pressure. ENT1 is an equilibrative transporter: it uses no ion gradient and simply moves adenosine down its concentration gradient, in either direction.

  • Caffeine works on this system at the receptor, not the transporter. It blocks adenosine receptors.
  • Alcohol inhibits ENT1, which raises adenosine and contributes to its sedating effect.

#System xc-: the cystine-glutamate exchanger

Carries: cystine in, glutamate out. Gene: SLC7A11.

This astrocyte exchanger swaps one glutamate out of the cell for one cystine in. It does two things at once.

  • Antioxidant supply. Cystine is the limiting ingredient for glutathione, the brain's main antioxidant.
  • Background glutamate. The glutamate it releases sets the low resting level outside synapses, which restrains further release through presynaptic receptors.

N-acetylcysteine feeds this exchanger. It has been tested in addiction, OCD-related conditions and other disorders, with mixed results.

#SNATs: the glutamine shuttle

Carries: glutamine. Genes: SLC38 family.

These transporters complete the glutamate-glutamine cycle from section 1. SNAT3 and SNAT5 release glutamine from astrocytes. SNAT1 and SNAT2 take it up into neurons, where it is turned back into glutamate or GABA. Without this shuttle, neurons would run out of both transmitters.

#The supply chain at the blood-brain barrier

The blood-brain barrier is a wall of tightly sealed cells lining the brain's blood vessels. Almost nothing water-soluble crosses it unaided, so the brain's fuel and the raw materials for its transmitters must be carried in.

TransporterGeneCarriesWhy it matters
GLUT1SLC2A1GlucoseThe brain's main fuel line
LAT1SLC7A5Large neutral amino acidsBrings in the precursors of serotonin, dopamine and noradrenaline
MCT1SLC16A1Lactate, ketone bodiesThe backup fuel line
P-glycoproteinABCB1Many drugs, outwardPumps foreign compounds back into the blood

#GLUT1: glucose

The brain is about 2% of body weight and uses about 20% of the body's glucose. GLUT1 carries that glucose across the barrier by facilitated diffusion, with no ion coupling. Neurons then take it up through GLUT3.

GLUT1 deficiency syndrome shows what happens when supply falls short: infant seizures, developmental delay and movement problems. The treatment is a ketogenic diet, which supplies ketone bodies that enter through MCT1 instead.

#LAT1: amino acid precursors

LAT1 carries tryptophan (for serotonin), tyrosine and phenylalanine (for dopamine and noradrenaline), and several other amino acids. They all compete for the same transporter. That competition has practical consequences.

  • Levodopa and meals. The Parkinson's drug levodopa enters the brain through LAT1. A high-protein meal can crowd it out and blunt the dose.
  • Phenylketonuria. Very high blood phenylalanine saturates LAT1 and starves the brain of other amino acids.
  • Drug delivery. Gabapentin and pregabalin also ride LAT1 into the brain.
  • Development. Rare LAT1 mutations cause autism with microcephaly.

#MCT1 and MCT2: lactate and ketones

MCT1 at the barrier and on astrocytes, and MCT2 on neurons, carry lactate and ketone bodies with a proton. They matter most during fasting, in infancy and on a ketogenic diet. Whether astrocytes routinely feed lactate to active neurons is still debated.

#P-glycoprotein: the bouncer

P-glycoprotein is not an SLC transporter. It is an ATP-powered pump that faces the blood and ejects a wide range of compounds. It is a major reason many drugs never reach the brain. Newer antihistamines such as fexofenadine cause little drowsiness partly because P-glycoprotein keeps them out.

#Patterns worth remembering

Six rules summarize the whole post. Each one lets you predict something about a transporter you have not studied.

  1. Termination defines the signal. How a transmitter is cleared sets how long it lasts and how far it spreads. Fast, tight clearance gives precise point-to-point signals. Slow, loose clearance gives broad, mood-like ones.
  2. Glia clear the fast transmitters; neurons recycle the slow ones. Astrocytes handle most glutamate and much GABA. Monoamine neurons take back their own transmitter.
  3. Location predicts effect. DAT is dense in the striatum and sparse in the prefrontal cortex. That one fact explains why DAT and NET drugs feel and act differently.
  4. The body map predicts side effects. SERT in gut and platelets, NET on the heart, VMAT2 in every monoamine neuron. A drug acts wherever its transporter is.
  5. Blockade is fast, benefit is slow. Transporters are occupied within hours. Clinical change often takes weeks, because the brain adapts to the new signal level.
  6. Gradients can fail. Transporters run on ion gradients. When energy supply collapses, they stall or reverse, and clearance becomes release.

#Two levers, opposite directions

LeverEffect on signallingExample
Block a surface transporterRaises it: transmitter stays in the synapse longerSSRIs on SERT
Block a vesicular transporterLowers it: each release delivers lessValbenazine on VMAT2

#Cheat sheet by condition

ConditionTransporter targetedTypical medicines
Depression, anxiety disordersSERT, sometimes with NETSSRIs, SNRIs
OCDSERTSSRIs at higher doses, clomipramine
ADHDDAT and NET, or NET aloneMethylphenidate, amphetamine salts; atomoxetine
Nerve painSERT and NETDuloxetine, nortriptyline
Focal epilepsyGAT1Tiagabine
Tardive dyskinesia, Huntington's choreaVMAT2Valbenazine, deutetrabenazine
Smoking cessationDAT and NETBupropion

This table describes mechanisms. It is not treatment guidance.

#What this post leaves out

This is a foundation, not a full catalogue. Four limits are worth stating plainly.

  • Coverage. About 25 of more than 400 SLC transporters appear here. Left out are the transporters for taurine, creatine, proline, D-serine, zinc and thyroid hormone, along with most ion exchangers.
  • Medicines only. The monoamine sections cover approved medicines. Non-medical drug use is outside the scope of this post.
  • Associations are not causes. Most links between a transporter and a psychiatric condition come from genetic association, post-mortem tissue or imaging. The rare single-gene disorders are the firm evidence.
  • Animal data. Several mechanisms here, such as uptake-2 limiting SSRI response, are shown in rodents and not yet confirmed in people.

Nothing here is medical advice.

#Sources

The claims below were checked against these sources on 16 November 2026. Each page was opened and the claim matched to its text.

ClaimSource
Glutamate transporters, generalDanbolt, Prog Neurobiol 2001
SLC6 family: SERT, DAT, NET, GATs, GlyTsKristensen et al., Pharmacol Rev 2011
Ion ratios for every transporterIUPHAR Concise Guide to Pharmacology 2019/20: Transporters
EAAT2 does about 95% of forebrain uptakePetr et al., J Neurosci 2015
More than 400 SLC transportersPizzagalli et al., FEBS J 2021
SERT structure and SSRI bindingColeman, Green and Gouaux, Nature 2016
SERT occupancy of about 80% at clinical dosesMeyer et al., Am J Psychiatry 2004
Serotonin and depression evidenceMoncrieff et al., Mol Psychiatry 2023
Candidate genes for depression not replicatedBorder et al., Am J Psychiatry 2019
About 95% of serotonin is made in the gutKoopman et al., Int J Mol Sci 2021
DAT knockout miceGiros et al., Nature 1996
NET clears dopamine in frontal cortexMorón et al., J Neurosci 2002
VMAT2, generalEiden and Weihe, Ann N Y Acad Sci 2011
Brain uses about 20% of glucoseMergenthaler et al., Trends Neurosci 2013
Ceftriaxone in ALSCudkowicz et al., Lancet Neurol 2014
Bitopertin in schizophreniaBugarski-Kirola et al., Biol Psychiatry 2017
Bitopertin FDA decision, February 2026HCPLive report
Iclepertin in schizophreniaKeefe et al., Lancet Psychiatry 2025
Valbenazine uses and warningFDA label
Deutetrabenazine uses and warningFDA label
Tetrabenazine use and warningFDA label
Viloxazine for ADHDFDA label
Tiagabine use and seizure warningFDA label
GAT1 gene and epilepsyCarvill et al., AJHG 2015
VGAT gene and epilepsyHeron et al., Neurology 2021
LAT1 gene and autism with microcephalyTărlungeanu et al., Cell 2016
VGLUT3 gene and hearing lossRuel et al., AJHG 2008
CHT1 gene and myasthenic syndromeBauché et al., AJHG 2016
VAChT gene and myasthenic syndromeO'Grady et al., Neurology 2016
GlyT2 gene and startle diseaseRees et al., Nat Genet 2006
GlyT1 gene and encephalopathyKurolap et al., AJHG 2016
EAAT1 gene and episodic ataxiaJen et al., Neurology 2005
NET gene and orthostatic intoleranceShannon et al., NEJM 2000
DAT gene and infant parkinsonism-dystoniaKurian et al., JCI 2009
GLUT1 deficiency and ketogenic dietKlepper et al., Epilepsia Open 2020

#Not individually sourced

These statements are standard textbook material but were not matched to an opened source.

  • Concentration figures: glutamate held a million times lower outside cells; vesicles concentrating monoamines 10,000 times
  • Uptake-2 limiting SSRI response in animals, and OCT3 inhibition by corticosterone
  • Alcohol inhibiting ENT1; N-acetylcysteine acting through system xc-
  • Levodopa competing with dietary protein at LAT1; fexofenadine kept out by P-glycoprotein
  • The reserpine and depression history
  • Tiagabine described as selective for GAT1 (the label names only the GABA uptake carrier)
[Contents]

Contents

[Jump to]

Jump to a section, post or action

Membership

Built for minds that think in systems.

Computermind is for the relentlessly curious: engineers, scientists and clinicians working where computer science meets neuroscience, who understand the brain deeply or are getting there. You're judged by what you contribute, not by your credentials.

  • models
  • code
  • datasets
  • papers
  • tools

We respect your privacy. No spam, ever.

your contributionmerged.merging…
[request an invite]

Tell us who's asking.

Membership is earned by contribution, so a little context helps us read your request well.

We respect your privacy. No spam, ever.